Skip to NavigationSkip to content's top 10 news stories of the week

Published on 02/04/21 at 11:00am
Top 10 news roundup

In the last week, a number of new COVID-19 developments have emerged; Novavax has delayed 100 million vaccines to the EU, GSK and Vir’s new treatment has shown 85% efficacy in a Phase III trial, and Pfizer has begun vaccine testing on young children.

 1. Novavax delays 100 million vaccines to the EUPublished 26/03/21

Novavax is delaying the signing of a contract to supply COVID-19 vaccines to the EU, as the company warned it was struggling to source some raw materials for the vaccine’s manufacture.

2. GSK & Vir’s COVID-19 treatment shows 85% efficacy in Phase III trial – Published 29/03/21

GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the treatment of COVID-19.

3. Pfizer begins COVID-19 vaccine testing on young children – Published 26/03/21

Pfizer have begun testing its COVID-19 vaccine on children under the age of 12, with the trials’ first participants, a pair of nine-year-old twins, being immunised at Duke University on 24 March.

4. 500,000 Moderna COVID-19 vaccines to arrive in UK next month – Published 29/03/21

More than 500,000 doses of Moderna’s COVID-19 vaccine are set to arrive in the UK next month, ministers have confirmed.

5. Roche’s SMA treatment Evrysdi approved by European Commission – Published 30/03/21

The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the treatment of patients aged 2 months or older with spinal muscular atrophy (SMA).

6. GSK to support manufacture of 60m Novavax COVID-19 vaccines Published 30/03/21

GSK has reached an agreement with Novavax and the UK Government Vaccines Taskforce to support the production of up to 60 million doses of Novavax’s COVID-19 vaccine, NVX-CoV2373, for use in the UK.

7. Celonic to manufacture at least 100 million CureVac COVID-19 jabsPublished 31/03/21

Celonic are to manufacture more than 100 million doses of CureVac’s COVID-19 vaccine, with 50 million shots expected to be produced before the end of this year.

8. Novartis expands targeted radioligand therapy pipelinePublished 30/03/21

Novartis has announced today that it has obtained exclusive rights to develop therapeutic applications for a library of fibroblast activation protein (FAP) targeting agents, including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics Inc.

9. FDA approve Astellas’s Myrbetriq treatment for bladder dysfunctionPublished 26/03/21

The FDA have approved a new indication for Astellas Pharma’s Myrbetriq and Myrbetriq Granules to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment in children aged three years and older.

10. Incyte receives EC approval for PemazyrePublished 30/03/21

Incyte have received approval from the European Commission (EC) for Pemazyre (pemigatinib), the first new treatment for adults with locally advanced or metastatic cholangiocarcinoma in over a decade.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches